{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:34:07Z","timestamp":1774085647604,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":186,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Choroid plexus carcinomas (CPC) are early childhood cancers characterized by loss of TP53 function and poor survival. We are analyzing data on TP53 status, survival, and second cancers from the largest cohort of CPC receiving chemotherapy followed by consolidation with marrow-ablative chemotherapy (HDCx). Additionally, we discuss the rationale for targeted therapies for CPC patients. Currently, 8 of the 13 with Li-Fraumeni Syndrome-associated CPC were treated and continued CPC-free, indicating that HDCx improves CPC-free survival in young children with TP53-mutated CPC. These data justify the inclusion of HDCx in the planned prospective international trial for children with TP53-mutated CPC.<\/jats:p>","DOI":"10.1093\/noajnl\/vdae109","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:33:38Z","timestamp":1720197218000},"source":"Crossref","is-referenced-by-count":4,"title":["Marrow-ablative consolidation chemotherapy and molecular targeted therapy delivered in a risk-adapted manner for newly diagnosed children with choroid plexus carcinoma: <i>A work in progress<\/i>"],"prefix":"10.1093","volume":"6","author":[{"given":"Maxim","family":"Yankelevich","sequence":"first","affiliation":[{"name":"Division of Oncology, St. Cristopher\u2019s Hospital for Children , Philadelphia , Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafik","family":"Zaky","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Lafay-Cousin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Oncology, Alberta Children\u2019s Hospital , Calgary, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Osorio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Adamski","sequence":"additional","affiliation":[{"name":"Birmingham Women\u2019s and Children\u2019s Hospital NHS Foundation Trust , Birmingham , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Kordes","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-6586","authenticated-orcid":false,"given":"Jonathan L","family":"Finlay","sequence":"additional","affiliation":[{"name":"Ohio State University College of Medicine, The Ohio State University , Columbus , Ohio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Prados","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Neurosurgery, University of California-San Francisco , San Francisco, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Neurosurgery, University of California-San Francisco , San Francisco, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"12","key":"2024072011211403600_CIT0001","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.2009.26.8169","article-title":"TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors","volume":"28","author":"Tabori","year":"2010","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024072011211403600_CIT0002","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1078-0432.CCR-14-1324","article-title":"Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups","volume":"21","author":"Merino","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2024072011211403600_CIT0003","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/pbc.23349","article-title":"Choroid plexus tumors; management, outcome and association with the li-fraumeni syndrome: the children\u2019s hospital los angeles (CHLA) Experience, 1991-2010","volume":"58","author":"Gozali","year":"2012","journal-title":"Pediatr Blood Cancer."},{"issue":"6","key":"2024072011211403600_CIT0004","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/neuonc\/noac274","article-title":"Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis","volume":"25","author":"Zaytseva","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024072011211403600_CIT0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13148-019-0708-z","article-title":"DNA methylation signature is prognostic of choroid plexus tumor aggressiveness","volume":"11","author":"Pienkowska","year":"2019","journal-title":"Clin Epigenetics."},{"issue":"30","key":"2024072011211403600_CIT0006","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2016.67.6940","article-title":"Genome-Wide DNA methylation analysis reveals epigenetic dysregulation of microRNA-34A in TP53-associated cancer susceptibility","volume":"34","author":"Samuel","year":"2016","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024072011211403600_CIT0007","doi-asserted-by":"crossref","first-page":"a005272","DOI":"10.1101\/mcs.a005272","article-title":"Molecular insights into malignant progression of atypical choroid plexus papilloma","volume":"7","author":"Yankelevich","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud."},{"issue":"6","key":"2024072011211403600_CIT0008","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/neuonc\/nov322","article-title":"Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups","volume":"18","author":"Thomas","year":"2016","journal-title":"Neuro Oncol."},{"issue":"2","key":"2024072011211403600_CIT0009","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bbrc.2017.11.192","article-title":"A new genetically engineered mouse model of choroid plexus carcinoma","volume":"496","author":"El Nagar","year":"2018","journal-title":"Biochem Biophys Res Commun."},{"issue":"9","key":"2024072011211403600_CIT0010","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/0008-5472.CAN-18-2565","article-title":"Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res."},{"issue":"95","key":"2024072011211403600_CIT0011","first-page":"72","article-title":"Hoeck, Anaelle Dumas, Gabriel Rosser, Yichen Li, Jennie Jeyapalan, Silvia Vicenzi, Qianhai Fan, Zeng Jie Yang, Arianna Sab\u00f2, Denise Sheer, Axel Behrens, and Silvia Marino. c-MYC overexpression induces choroid plexus papillomas through a T-cell mediated inflammatory mechanism","volume":"7","author":"Ashirwad","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"2024072011211403600_CIT0012","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00401-014-1348-1","article-title":"Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors","volume":"128","author":"Mangerel","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2024072011211403600_CIT0013","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ccell.2015.04.005","article-title":"Cross-species genomics identifies TAF12, NFYC, and RAD54L as choroid plexus carcinoma oncogenes","volume":"27","author":"Tong","year":"2015","journal-title":"Cancer Cell."},{"issue":"1","key":"2024072011211403600_CIT0014","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11060-014-1473-7","article-title":"Methylation of the hTERT promoter is frequent in choroid plexus tumors but not of independent prognostic value","volume":"119","author":"Ruland","year":"2014","journal-title":"J Neurooncol."},{"issue":"6","key":"2024072011211403600_CIT0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3171\/2010.3.PEDS09354","article-title":"Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma","volume":"5","author":"Lafay-Cousin","year":"2010","journal-title":"J Neurosurg Pediatr."},{"issue":"5","key":"2024072011211403600_CIT0016","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.25436","article-title":"Choroid plexus carcinoma in children \u2013 the head start experience","volume":"62","author":"Zaky","year":"2015","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"2024072011211403600_CIT0017","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11060-021-03942-0","article-title":"Final results of the choroid plexus tumor study CPT-SIOP-2000","volume":"156","author":"Wolff","year":"2022","journal-title":"J Neurooncol."},{"issue":"1","key":"2024072011211403600_CIT0018","first-page":"vdaa168","article-title":"Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: Results from the SJYC07 trial","volume":"3","author":"Liu","year":"2020","journal-title":"Neurooncol. Adv.."},{"key":"2024072011211403600_CIT0019","first-page":"652","article-title":"Molecular guided therapy provides sustained clinical response in refractory choroid plexus carcinoma","volume":"8","author":"Albert","year":"2017","journal-title":"Case Reports Front Pharmacol"},{"issue":"3","key":"2024072011211403600_CIT0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/modpathol.3800989","article-title":"Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas","volume":"21","author":"Nupponen","year":"2008","journal-title":"Mod Pathol."},{"issue":"4","key":"2024072011211403600_CIT0021","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ncb3327","article-title":"Sonic Hedgehog promotes proliferation of Notch-dependent monociliated choroid plexus tumour cells","volume":"18","author":"Li","year":"2016","journal-title":"Nat Cell Biol."},{"key":"2024072011211403600_CIT0022","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jconrel.2023.04.016","article-title":"Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma","volume":"357","author":"Martin","year":"2023","journal-title":"J Control Release."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdae109\/58454031\/vdae109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdae109\/58603106\/vdae109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdae109\/58603106\/vdae109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T11:21:32Z","timestamp":1721474492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdae109\/7708033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdae109","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"vdae109"}}